Tango Therapeutics : Corporate Presentation

Targeting tumor suppressor loss

to unmask vulnerabilities in cancer

for the next generation of precision medicines

Corporate Overview

February 2022

Confidential | 1

Disclaimer and Safe Harbor Statement

Certain statements in this presentation may be considered forward-looking statements. Forward-looking statements generally relate to future events, Tango's future financial and operating performance, goals, expectations, beliefs, development plans and development objectives for Tango's product pipeline. In some cases, you can identify forward-looking statements by terminology such as "may", "should", "expect", "intend", "will", "path", "achievable", "milestones", "goal", "forecast", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. For example, statements concerning the following include or constitute forward-looking statements: Tango has a sustainable pipeline of novel drugs and drug programs; the Company has multiple drug candidates planned for 2022; TNG908 is a potentially first in class PRMT5 inhibitor that is synthetic lethal with MTAP deletion; the expected timing of: (i) development candidate declaration for certain targets, (ii) initiating IND-enabling studies; (iii) filing INDs, (iv) clinical trial initiation and (v) the release of preliminary safety and efficacy data and final safety and efficacy data from clinical trials; the Company has a sustainable precision oncology pipeline of novel targets; the anticipated benefits of synthetic lethal drugs; there is a clear path to clinical POC in MTAP-null solid tumors with multiple histologies; TNG908's large therapeutic index expected to allow selection of optimal efficacious dose below MTD; the Company will be pursuing novel combination therapies with inhibitors that have a complementary mechanism of action; potential for accelerated regulatory approval of TNG908 in MPNST (and the potential option for a histology agnostic approval for TNG908); potential for future TNG908 expansion cohorts to evaluate activity in a range of histologies and optionality for multiple registration strategies; one of the largest genetically defined patient populations may benefit from the PRMT5 franchise; Tango is planning multiple rational combination trials in PRMT5 franchise based on strong pre-clinical synergy data; next generation PRMT5 compounds will follow TNG908 by 12-18 months; the TNG908 composition of matter patent applications will provide meaningful patent protection through at least 2041; the Company's belief regarding a strong IP position for USP1 pipeline product; synergy of USP1 in both PARP-sensitiveand -resistancemodels suggests potential to meaningfully expand patient benefit from PARP inhibitor; Tango's ability to identify, develop and commercialize drug candidates; the anticipated benefits of future product candidates including those identified in the future through the Tango discovery platform; the STK11 mutation enables the first potential genetic patient selection for an immuno-oncology clinical trial; and Tango has a cash balance that provides a runway into second half of 2024 (and is sufficient to achieve multiple projected key milestones). Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Tango and its management are inherently uncertain. Drug development and commercialization involves a high degree of risk, and only a small number of research and development programs result in commercialization of a product. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: Tango has a limited operating history and has not generated any revenue to date from drug sales, and may never become profitable; Tango has limited experience with conducting clinical trials (and will rely on a third party to operate the clinical trial for TNG908) and may not be able to commence the clinical trial when expected and may not generate results in the anticipated timeframe (or at all); the benefits of Tango pipeline products and potential combination therapies that are seen in pre-clinical experiments may not be present in clinical trials or in use commercially or may not be safe and/or effective in humans (and Tango or a third-party may not be able to obtain approval or commercial sales of any combination therapies); Tango has incurred significant operating losses and anticipates continued losses for the foreseeable future; we will need to raise capital in the future and if we are unable to raise capital when needed or on attractive terms, we would be forced to delay, scale back or discontinue some of our development programs or future commercialization efforts; we may be unable to advance our preclinical development programs into and through the clinic for safety or efficacy reasons or experience significant delays in doing so as a result of factors beyond Tango's control; Tango's approach to the discovery and development of product candidates is novel and unproven, which makes it difficult to predict the time, cost of development, and likelihood of successfully developing any products; Tango may not identify or discover development candidates (including next generation products) or may expend limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success; delays or difficulties in the initiation or enrollment of patients in clinical trials could delay or prevent receipt of regulatory approvals; our products candidates may cause adverse or other undesirable side effects that could, among other things, delay or prevent regulatory approval; our dependence on third parties for conducting clinical trials and producing drug product; our ability to obtain and maintain patent and other intellectual property protection for our technology and product candidates or the scope of intellectual property protection obtained is not sufficiently broad; and delays and other impacts on product development and clinical trials from the COVID-19 pandemic. Additional information concerning risks, uncertainties and assumptions can be found in Tango's filings with the SEC, including the risk factors referenced in Tango's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 as filed with the SEC on November 9, 2021. You should not place undue reliance on forward-looking statements in this presentation, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Tango specifically disclaims any duty to update these forward-looking statements.

Certain information contained in this Presentation relates to or is based on studies, publications, surveys and Tango's own internal estimates and research. In addition, the market data included in this presentation involve a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while Tango believes its internal research is reliable, such research has not been verified by any independent source.

Confidential | 2

COMPANY OVERVIEW

Confidential | 3

Tango summary





Precision oncology company based on synthetic lethality, combining discovery and clinical development in the same genetic context

Expanding oncology target space into tumor suppressor gene loss with a productive, state-of-the-art discovery platform

Sustainable pipeline of novel drug programs for cancers with specific tumor suppressor gene loss and bringing precision medicine to immuno-oncology with multiple development candidates planned for 2022

TNG908 is a potentially first-in-class synthetic lethal PRMT5 inhibitor for MTAP-deleted tumors with initiation of Phase 1/2 clinical trial in 1H 2022

Broad strategic collaboration with Gilead based on immune evasion effects of tumor suppressor gene loss

• Management team with deep expertise in cancer genetics, drug discovery, clinical development and extensive pharmaceutical experience backed by top-tier investors

Confidential | 4

Leaders in drug discovery, cancer biology, functional genomics and translational medicine

LEADERSHIP

BOARD OF DIRECTORS

Barbara Weber, MD	Alan Huang, PhD	Daniella Beckman	Marc Rudoltz, MD
CEO	CSO	CFO	CMO

Charles Davis, PhD	Doug Barry	John Ross
Pharmaceutical Sciences	General Counsel	Human Resources

Heather	Jannik	Bill	John
DiBenedetto	Andersen, PhD	Mallender, PhD	Maxwell, PhD
Development Operations	Biology	Biochemistry	Chemistry

Alexis Borisy	Lesley Calhoun
Chairman

Aaron Davis

Reid Huber, PhD

Malte Peters, MD

Mace Rothenberg, MD

Barbara Weber, MD

Confidential | 5